Piramal Pharma Limited operates across pharmaceutical manufacturing, contract development and manufacturing (CDMO), hospital generics, and consumer healthcare. The company serves global pharmaceutical innovators through integrated manufacturing and research capabilities. A diversified portfolio across regulated markets reduces dependence on individual product segments. Growing outsourcing trends in pharmaceutical manufacturing create significant business opportunities. Investments in capacity expansion and complex formulations support future growth.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹25,809 cr | ₹9,205 cr | ₹-314 cr | — | -2.37 | 3.16 | -4.0% | 1.1% | 0.8% | 0.67 | ₹776 cr | 32.5 | 1.11 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 2,270 | -69 | -0.52 | — | +17.4% | -3.1% |
| Mar 2026 | 2,752 | -9 | -0.07 | -106.0% | -0.1% | -0.3% |
| Dec 2025 | 2,140 | -136 | -1.03 | -3533.3% | -2.9% | -6.4% |
| Sep 2025 | 2,044 | -99 | -0.75 | -541.2% | -8.8% | -4.9% |
| Jun 2025 | 1,934 | -82 | -0.62 | — | -0.9% | -4.2% |
| Mar 2025 | 2,754 | 154 | 1.16 | +50.6% | +7.9% | 5.6% |
| Dec 2024 | 2,204 | 4 | 0.03 | -62.5% | +12.5% | 0.2% |
| Sep 2024 | 2,242 | 23 | 0.17 | +325.0% | +17.3% | 1.0% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✓ Pass |
| Annual EPS up 25%+ in each of the last 2 years | ✗ Fail |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 133.27 ✓ Within 25% of the 52-week high · high 226.62 ✗ RS percentile 70 or more · RS 67 Trend template - the gate, measured: a modest 21-day edge. | 6/8 | 6 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | — C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 226.62 ✓ S more volume on up days than down days (50 sessions) · 1.35x ✗ L RS percentile 80 or more · RS 67 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 3/5 | Average |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 231.93 ✓ Box bottom confirmed (3 sessions holding) · bottom 191.41 ✗ Close above the box top · close 194.44 ✗ Volume at least 1.5x its 50-day average · 0.3x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 45/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 231.93 ✗ Close above the prior 20-session high · 216.70 ✗ Close below the prior 20-session low · 191.41 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 3.1% — Return on capital (ROCE) · 0.8% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 5/100 | Weak |
| Graham | Needs positive earnings and book value. | Not assessable | |
| Piotroski | ✗ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✓ Cash flow above net profit (earnings quality) ✗ Long-term debt / assets falling ✗ Current ratio rising · 1.51 ✗ No new shares issued ✗ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 2/9 | Weak |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PPLPHARMA this stock | -6.6 | +8.7 | +30.7 | +0.9 | +96.2 | — | — | 3.16 | -4.0 | 0.8 | — | 0.67 | 32.5 | 25,809 | 9,205 | -314 | -2.4 | 1.11 |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ZIMLAB | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |